Positron Emission Tomography (PET) Nuclear Medicine Market Report 2026

The positron emission tomography (pet) nuclear medicine market size has grown rapidly in recent years. It will grow from $13.16 billion in 2025 to $15.06 billion in 2026 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to increasing cancer diagnosis rates, expansion of nuclear medicine facilities, widespread use of f-18 radiotracers, growth in cardiology imaging applications, improvements in radiopharmaceutical production.

The positron emission tomography (pet) nuclear medicine market size is expected to see rapid growth in the next few years. It will grow to $25.7 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to increasing investments in molecular imaging, rising demand for personalized medicine diagnostics, expansion of neurological imaging applications, advancements in radiotracer development, growing adoption of hybrid imaging systems. Major trends in the forecast period include increasing adoption of advanced radiotracers, growing use of pet imaging in oncology, rising integration of pet with ct and mri systems, expansion of precision diagnostic imaging applications, enhanced focus on early disease detection.

The increasing prevalence of chronic diseases is expected to drive the growth of the positron emission tomography nuclear medicine market going forward. Chronic diseases are long term health conditions that usually persist for three months or longer and often require continuous medical care or limit daily activities. The rise in chronic diseases is mainly associated with factors such as aging populations, reduced physical activity, unhealthy dietary habits, and exposure to environmental risks. Positron emission tomography nuclear medicine supports the management of chronic diseases by providing advanced imaging techniques that enable early disease detection, accurate diagnosis, and continuous monitoring of disease progression. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, more than 35 million new cancer cases are projected globally by 2050, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the increasing burden of chronic diseases is driving the growth of the positron emission tomography nuclear medicine market.

Major companies operating in the positron emission tomography nuclear medicine market are focusing on developing technologically advanced products, such as PET slice scanners, to deliver high resolution imaging of metabolic activity. A PET slice scanner is a medical imaging system that combines positron emission tomography with advanced computing to generate detailed cross sectional images of metabolic processes in the body, supporting the detection and monitoring of diseases, particularly cancer. For instance, in July 2024, Positron Corporation, a US-based nuclear medicine company, launched the NeuSight PET-CT 3D 64-slice scanner. This system combines advanced imaging technology with improved patient comfort and operational efficiency and is designed to enhance cardiac PET imaging while supporting oncology and neurology studies. With faster scanning speeds, improved accuracy, and comprehensive anatomic and functional imaging, the NeuSight PET-CT supports heart, tumor, and brain imaging across multiple molecular imaging applications.

In February 2023, Lantheus Holdings Inc., a US-based radiopharmaceutical company, acquired Cerveau Technologies Inc. for an undisclosed amount. This acquisition supports Lantheus’s growth strategy by expanding its radiopharmaceutical diagnostic imaging portfolio to include a widely used tau PET imaging agent for Alzheimer’s disease. It also strengthens the company’s position through expanded academic collaborations and pharmaceutical partnerships. Cerveau Technologies Inc. is a US-based company specializing in F 18-labeled positron emission tomography imaging agents that target tau tangles associated with Alzheimer’s disease.

Major companies operating in the positron emission tomography (pet) nuclear medicine market are Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Canon Medical Systems Corporation, Fujifilm Holdings Corporation, Shimadzu Corporation, Toshiba America Medical Systems Inc., Mediso Medical Imaging Systems Ltd., Lantheus Holdings Inc., Jubilant DraxImage Inc., Advanced Accelerator Applications, Eckert & Ziegler Strahlen- und Medizintechnik AG, Cardinal Health, NorthStar Medical Radioisotopes LLC, Bruker Corporation, Digirad Corporation, Neusoft Medical Systems Co. Ltd., Agfa HealthCare NV, Bayer AG, Positron Corporation.

North America was the largest region in the positron emission tomography (PET) nuclear medicine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the positron emission tomography (pet) nuclear medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the positron emission tomography (pet) nuclear medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the positron emission tomography nuclear medicine market by increasing costs of imported cyclotrons, imaging scanners, radiopharmaceutical production equipment, and detector components. Hospitals and diagnostic centers in North America and Europe are most affected due to reliance on imported high-end imaging systems, while Asia-Pacific faces higher capital costs for facility expansion. These tariffs are increasing overall procedure costs and slowing equipment upgrades. However, they are also driving domestic radiotracer production, regional equipment assembly, and long-term investment in local nuclear medicine infrastructure.

The positron emission tomography (pet) nuclear medicine market research report is one of a series of new reports that provides positron emission tomography (pet) nuclear medicine market statistics, including positron emission tomography (pet) nuclear medicine industry global market size, regional shares, competitors with a positron emission tomography (pet) nuclear medicine market share, detailed positron emission tomography (pet) nuclear medicine market segments, market trends and opportunities, and any further data you may need to thrive in the positron emission tomography (pet) nuclear medicine industry. This positron emission tomography (pet) nuclear medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Positron emission tomography nuclear medicine is a medical imaging technique that uses radioactive substances to visualize and evaluate metabolic activity within the body. It involves administering a small quantity of radioactive material, known as a radiotracer, which enables the detection of cellular level changes and supports early disease diagnosis.

The main types of positron emission tomography nuclear medicines include F-18, RB-82, and others. F-18, or fluorine-18, is a radioactive isotope widely used in positron emission tomography imaging. It is utilized across various procedures such as diagnostic procedures, single photon emission computed tomography procedures, positron emission tomography procedures, therapeutic procedures, beta emitter procedures, alpha emitter procedures, and brachytherapy procedures. These applications support clinical areas including oncology, cardiology, neurology, and others and are used by end users such as hospitals, diagnostic centers, and research institutes.

The positron emission tomography (PET) nuclear medicine market consists of sales of radiotracers, dose calibrators, injection systems, patient monitoring systems and simulation tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.